Breathtec Biomedical, Inc.
Breathtec Biomedical, Inc. (“Breathtec”) was formed to propel innovative research in the area of breath analysis as a medical screening tool. Our efforts are aimed at leading the development of commercially viable methods for the early screening of diseases such as lung & breast cancers, neurodegenerative diseases (eg: Alzheimer’s / Parkinson’s), tuberculosis, diabetes, liver disease and more.
Our primary avenue of investigation is focused on innovation and advances in the field of specialized mass spectrometry.
The principal market opportunity arises from the potential of low-cost, non-intrusive diagnostic screening in general medical practice which could lead to notable advances in early detection of major cancers and other life-altering diseases.
Regular screening using a simple breath test, could lead to significant advancements in remedial treatment protocols targeting major improvements in survivability and life quality.
Research from Breathtec’s Scientific Advisor Dr. Richard A. Yost has involved over 100 graduate students funded by over $40 million in research grants, and has published over 160 papers and 16 patents. Over $30 billion worth of instruments have been sold based on these patents.